Form 4: Solid Biosciences Director Ilan Ganot Reports Stock Option Grant

Director Ilan Ganot of Solid Biosciences Inc. reports the acquisition of stock options.

Summary

• On June 11, 2024, Ilan Ganot, a director of Solid Biosciences Inc., was granted stock options to purchase 34,400 shares of common stock.
• The exercise price of these options is $7.51 per share.
• The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date.
• The options will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
• The options expire on June 11, 2034.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant (34,400 shares) would need to be compared to grants at peer companies of similar market capitalization and stage of development to assess its relative value.
• Companies like Sarepta Therapeutics and BioMarin Pharmaceutical also use stock options as part of their director compensation.

Key Dates